European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
National Virus Reference Laboratory (NVRL), University College Dublin, Dublin, Ireland.
Euro Surveill. 2021 Apr;26(16). doi: 10.2807/1560-7917.ES.2021.26.16.2100348.
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).
我们比较了 19207 例 SARS-CoV-2 变异株 B.1.1.7/S 基因目标失败(SGTF)、436 例 B.1.351 和 352 例 P.1 与七个欧洲国家报告的非变异病例。这些变异株引起的 COVID-19 病例住院的校正比值比显著升高(B.1.1.7/SGTF:1.7,95%置信区间(CI):1.0-2.9;B.1.351:3.6,95%CI:2.1-6.2;P.1:2.6,95%CI:1.4-4.8),B.1.1.7/SGTF 和 P.1 病例也需要重症监护入院(B.1.1.7/SGTF:2.3,95%CI:1.4-3.5;P.1:2.2,95%CI:1.7-2.8)。